Ask about this productRelated genes to: PRKX antibody
- Gene:
- PRKX NIH gene
- Name:
- protein kinase X-linked
- Previous symbol:
- -
- Synonyms:
- PKX1
- Chromosome:
- Xp22.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-22
- Date modifiied:
- 2018-04-26
- Gene:
- PRKY NIH gene
- Name:
- protein kinase Y-linked (pseudogene)
- Previous symbol:
- -
- Synonyms:
- PRKYP, PRKXP3
- Chromosome:
- Yp11.2
- Locus Type:
- pseudogene
- Date approved:
- 1995-11-22
- Date modifiied:
- 2018-04-30
Related products to: PRKX antibody
Related articles to: PRKX antibody
- 46,XX testicular disorder/difference of sex development (46,XX DSD) is a rare congenital condition, characterized by a combination of the typical female sex chromosome constitution, 46,XX, and a variable male phenotype. In the majority of individuals with 46,XX DSD, a Y chromosome segment containing the sex-determining region gene (SRY) has been translocated to the paternal X chromosome. However, the precise genomic content of the translocated segment and the genome-wide effects remain elusive. - Source: PubMed
Publication date: 2024/10/08
Berglund AgnetheJohannsen Emma BSkakkebæk AnneChang SimonRohayem JuliaLaurentino SandraHørlyck ArneDrue Simon OBak Ebbe NorskovFedder JensTüttelmann FrankGromoll JörgJust JesperGravholt Claus H - The translocation of SRY onto one of the two X chromosomes results in a 46,XX testicular disorder of sex development; this is supposedly because of non-allelic homologous recombination between the protein kinase X gene (PRKX) and the inverted protein kinase Y pseudogene (PRKY). Although 46,XX SRY-positive men are infertile, the literature data indicate that some of these individuals are of short stature (relative to the general population). We sought to determine whether short stature was linked to additional, more complex chromosomal rearrangements. - Source: PubMed
Publication date: 2022/09/07
Capron CélineJanuel LouisVieville GaëlleJaillard SylvieKuentz PaulSalaun GaëlleNadeau GwenaëlClement PatriceBrechard Marie PierreHerve BéréniceDupont Jean MichelGruchy NicolasChambon PascalAbdelhedi FatmaDahlen EricVago PhilippeHarbuz RaduPlotton IngridCoutton CharlesBelaud-Rotureau Marc-AntoineSchluth-Bolard CarolineVialard François - Chemoproteomics is a key platform for characterizing the mode of action for compounds, especially for targeted protein degraders such as proteolysis targeting chimeras (PROTACs) and molecular glues. With deep proteome coverage, multiplexed tandem mass tag-mass spectrometry (TMT-MS) can tackle up to 18 samples in a single experiment. Here, we present a pooling strategy for further enhancing the throughput and apply the strategy to an FDA-approved drug library (95 best-in-class compounds). The TMT-MS-based pooling strategy was evaluated in the following steps. First, we demonstrated the capability of TMT-MS by analyzing more than 15 000 unique proteins (> 12 000 gene products) in HEK293 cells treated with five PROTACs (two BRD/BET degraders and three degraders for FAK, ALK, and BTK kinases). We then introduced a rationalized pooling strategy to separate structurally similar compounds in different pools and identified the proteomic response to 14 pools from the drug library. Finally, we validated the proteomic response from one pool by reprofiling the cells via treatment with individual drugs with sufficient replicates. Interestingly, numerous proteins were found to change upon drug treatment, including AMD1, ODC1, PRKX, PRKY, EXO1, AEN, and LRRC58 with 7-hydroxystaurosporine; C6orf64, HMGCR, and RRM2 with Sorafenib; SYS1 and ALAS1 with Venetoclax; and ATF3, CLK1, and CLK4 with Palbocilib. Thus, pooling chemoproteomics screening provides an efficient method for dissecting the molecular targets of compound libraries. - Source: PubMed
Publication date: 2022/08/15
Sun HuanYang KaZhang XueFu YingxueYarbro JayWu ZhipingChen Ping-ChungChen TaoshengPeng Junmin - 46,XX testicular disorder of sex development (46,XX TDSD) is a relatively rare condition characterised by the presence of testicular tissue with 46,XX karyotype. The present study aims to reveal the phenotype to genotype correlation in a series of sex-determining region Y (SRY)-positive 46,XX TDSD cases. We present the clinical findings, hormone profiles and genetic test results of six patients with SRY-positive 46,XX TDSD and give the details and follow-up findings of our three of previously published patients. All patients presented common characteristics such as azoospermia, hypergonadotropic hypogonadism and an SRY gene translocated on the terminal part of the short arm of one of the X chromosomes. Mean ± standard deviation (SD) height of the patients was 164.78 ± 8.0 cm. Five patients had decreased secondary sexual characteristics, and three patients had gynaecomastia with varying degrees. Five of the seven patients revealed a translocation between protein kinase X (PRKX) and inverted protein kinase Y (PRKY) genes, and the remaining two patients showed a translocation between the pseudoautosomal region 1 (PAR1) of X chromosome and the differential region of Y chromosome. X chromosome inactivation (XCI) analysis results demonstrated random and skewed XCI in 5 cases and 1 case, respectively. In brief, we delineate the phenotypic spectrum of patients with SRY-positive 46,XX TDSD and the underlying mechanisms of Xp;Yp translocations. - Source: PubMed
Publication date: 2020/09/03
Akar Omer SalihGunes SezginAbur UmmetAltundag EnginAsci RamazanOnat Onur EmreOzcelik TayfunOgur Gonul - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer tumors. Comparisons between TNBC and non-triple negative breast cancer (nTNBC) may help to differentiate key components involved in TNBC neoplasms. The purpose of the study was to analyze the expression profile of TNBC versus nTNBC tumors in a homogeneous population from northeastern Mexico. A prospective study of 50 patients was conducted (25 TNBC and 25 nTNBC). Clinic parameters were equally distributed for TNBC and nTNBC: age at diagnosis (51 vs 47 years, p=0.1), glucose levels (107 mg/dl vs 104 mg/dl, p=0.64), and body mass index (28 vs 29, p=0.14), respectively. Core biopsies were collected for histopathological diagnosis and gene expression analyses. Total RNA was isolated and expression profiling was performed. 40 genes showed differential expression pattern in TNBC tumors. Among these, 9 over-expressed genes (, and ), and one under-expressed () gene are involved in general metabolism. Based on this biochemical peculiarity, and the over-expression of and (involved in tumor growth and metastasis, respectively) we validated by qPCR the expression profile of 7 genes out of the signature. In this report, a new gene signature for TNBC is proposed. To our knowledge, this is the first TNBC signature which describes genes involved in general metabolism. The findings may be pertinent for Mexican patients and require to be evaluated in further ethnic groups and populations. - Source: PubMed
Publication date: 2017/05/04
Santuario-Facio Sandra KarinaCardona-Huerta ServandoPerez-Paramo Yadira XitlalliTrevino VictorHernandez-Cabrera FranciscoRojas-Martinez AugustoUscanga-Perales GreciaMartinez-Rodriguez Jorge LuisMartinez-Jacobo LizethPadilla-Rivas GerardoMuñoz-Maldonado GerardoGonzalez-Guerrero Juan FranciscoValero-Gomez JavierVazquez-Guerrero Ana LorenaMartinez-Rodriguez Herminia GuadalupeBarboza-Quintana AlvaroBarboza-Quintana OraliaGarza-Guajardo RaquelOrtiz-Lopez Rocio